Ocrelizumab Biosimilar (Sandoz)

奥瑞珠单抗生物类似药 (山德士)

Report date: 2025/04/20 20:00:03

Base Information

Drug NameOcrelizumab Biosimilar (Sandoz)
Drug Alias NameCYB-704
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsAnti-CD20 +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBosnia and HerzegovinaBulgariaUnited States +[8] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesSandoz
China Registration ClassN/A

Develop Information

Active CompaniesSandoz
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A